February 6, 2026 4:45pm

As I wrote this a.m., “Ricochet … Climbing out-of-the-hole” Right again after yet another again!

Friday benefited from rotation after being weighed down by tech and C&GT sector selling

Pre-open Indications: 4 Hits

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

TGIF

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!  I’m NOT at all writing a doom-and-gloom predictions as I am more frequently right than consequentially wrong; I am mostly EARLY in my prognostications!

 

RMi Pre-opening: Ricochet … https://www.regmedinvestors.com/articles/14301   

RMi Finance Note: Sangamo Therapeutics (SGMO) Offering 35.19 M shares priced at $0.4719 … https://www.regmedinvestors.com/articles/14295   

 

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

Friday: The Dow closed UP +1206.95 points or +2.47%, the S&P closed UP +133.90 points or +1.97% while the Nasdaq closed UP +490.627 points or +2.18%

  • Theme of the session: Stocks surged

Friday’s (my) 40-company covered sector’s advance/decline line opened positive with 34 incliners, 4 decliners and 2 flats, ending with a positive close of 35 incliners, 5 decliners and 0 flat

  • Small caps surged Friday, with the iShares Russell 2000 ETF (IWM) up by more than 3%

Henry’omics: We need to more than consider the macro-economic environment to comprehend the cause and effect of the macro versus micro data affecting “our” universe of cell and gene therapy (C&GT) sector

  • Consumer sentiment brightened a bit to start February as near-term inflation expectations plunged. The University of Michigan Survey of Consumers showed a headline reading of 57.3, up 1.6% from January and better than the 55.0 consensus estimate. The index rose 5.2% to 58.3. Both gauges were off more than 11% from their same levels a year ago. On inflation, the 1-year outlook came in at 3.5%, down 1/2 % point from January and the lowest since January 2025. The 5-year view nudged higher to 3.4%.

The CBOE Fear (VIX) index, Friday at 17.75, after Thursday’s 21.63, Wednesday’s 19.25, Tuesday’s 17.91, Monday’s 16.53 and last Friday’s 17.66

Metrics: Friday …

  • The RUT was up +92.69 points or +3.60%,
  • The XLV was up +2.87 points or +1.85%,
  • The NBI was up +174.38 points or +3%;
  • The XBI was up +4.76 points or +3.94%
  • The IWM was up +9.19 or +3.59%;
  • The IBB was up +4.94 points or +2.91%,
  • The VIX was down -4.02 points or -18.48% at to 17.75

 

Q1/26 February – 3 negative and 2 positive sessions

  • January – 2 holidays, 2 neutral, 9 negative and 9 positive closes

Q4/25 …

  • December – 1 holiday, 8 positive and 14 negative closes
  • November – 1 holiday, 8 positive and 11 negative closes
  • October -1 neutral, 11 positive and 12 negative closes

 

Friday Closing UP (10 of 35)

  • Vertex (VRTX +$19.11 after Thursday’s -$11.71, Wednesday’s +$4.91, Tuesday’s -$6.40 and Monday’s +$2.11),
  • IQIA Holdings (IQV +$6.53 after Thursday’s -$21.85, Wednesday’s -$1.48, Tuesday’s -$27.54, and Monday’s +$1.01),
  • Ionis Pharmaceuticals (IONS +$3.02),
  • CRISPR Therapeutics (CRSP +$2.86 after Thursday’s -$4.29, Wednesday’s -$1.83, Tuesday’s +$0.69 and Monday’s +$1.35),
  • Supernus Therapeutics (SUPN +$2.28 after Thursday’s +$0.29, Wednesday’s +$0.68, Tuesday’s -$0.38 and Monday’s +$0.62),
  • Beam Therapeutics (BEAM +$1.79 after Thursday’s -$2.22 and Wednesday’s -$0.94),
  • Capricor Therapeutics (CAPR +$1.69),
  • Sarepta Therapeutics (SRPT +$1.47 after Thursday’s -$2.70),
  • Intellia Therapeutics (NTLA +$1.19),
  • uniQure NV (QURE +$1.13 after Thursday’s -$2.13 after Wednesday’s -$1.15, Tuesday’s +$3.10 and Monday’s +$1.98),

Flat (0)

Friday’s Closing DOWN (5 of 5):

  • Alnylam Pharmaceuticals (ALNY -$3.08 after Thursday’s -$20.72, Wednesday’s +$0.16, Tuesday’s +$12.69 and Monday’s +$1.05),
  • Generation Bio (GBIO -$0.40 after Thursday’s +$0.12),
  • Mesoblast (MESO -$0.13),
  • Arrowhead Pharmaceuticals (ARWR -$0.12 after Thursday’s -$3.42 and Wednesday’s -$4.08)
  • Brainstorm Cell Therapeutics (BCLI -$0.01),

 

 

The Bottom Line: More of the … WHY

Sector earnings have started in this 1st week of a new February, after a mixed week of ups, and downs.

Friday’s HUGE rally for the Dow and other major stock indexes Friday came after a rocky week for tech names bouncing from last night lows

  • Up more than 2%, the Dow breached the 50,000 mark for the first time and held above that level in recent action with a gain of 1,206 points.
  • The S&P 500 also rose, with the benchmark index rising 1.8% in recent action.
  • The Nasdaq looked to halt a 3-day losing streak with its 2% jump. In the Nasdaq-100 index,

The week began bleak as we headed into Friday, with the S&P 500 on pace for its worst week since last October and the Nasdaq on track for its worst week.

 

Earnings release dates:

  • 2/12 – Alnylam Pharmaceuticals (ALNY), Vertex (VRTX) and Ultragenyx Pharmaceuticals (RARE)
  • 2/13 – Moderna (MRNA)

 

RISK is always a factor remaining below the surface …  boiled-up as slight shocks of profiteering on upsides shook but not rocked the C&GT sector and markets!

  • As I have written, cash is always ... king for investors who want to keep some liquidity and avoid having to sell in a down market,

 

February – 1st week

  • 2/6 – Friday closed positive with 35 incliners, 5 decliners and 0 flat
  • 2/5 -Thursday closed negative with 2 incliners, 36 decliners and 2 flats
  • 2/4 -Wednesday closed negative with 10 incliners, 29 decliners and 1 flat               
  • 2/3 -Tuesday closed negative with 18 incliners, 21 decliners and 1 flat      
  • 2/2 - Monday closed positive with 29 incliners, 10 decliners and 1 flat

January – 5th week:

  • 1/30 – Friday closed negative with 6 incliners, 32 decliners and 2 flat
  • 1/29 - Thursday closed positive with 22 incliners, 17 decliners and 1 flat
  • 1/28 - Wednesday closed negative with 4 incliners, 35 decliners and 1 flat
  • 1/27 - Tuesday closed positive with 21 incliners, 19 decliners and 0 flat
  • 1/26 -Monday closed positive with 19 incliners, 18 decliners and 3 flats

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Friday: Vertex (VRTX), IQIA Holdings (IQV) and Ionis Pharmaceuticals (IONS)
  • Thursday: Supernus Therapeutics (SUPN) and Generation Bio (GBIO)
  • Wednesday: Vertex (VRTX), Supernus therapeutics (SUPN) and Moderna (MRNA)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), uniQure NV (QURE) and Capricor Therapeutics (CAPR)
  • Monday: Arrowhead Pharmaceuticals (ARWR), Vertex (VRTX) and UniQure NV (QURE)

The worst three (3) in the session: Losers

  • Friday: Alnylam Pharmaceuticals (ALNY), Moderna (MRNA) and Generation Bio (GBIO)
  • Thursday: IQIA Holdings (IQV), Alnylam Pharmaceuticals (ALNY) and Vertex (VRTX)
  • Wednesday: Arrowhead Pharmaceuticals (ARWR), CRISPR Therapeutics (CRSP) and IQIA Holdings (IQV)
  • Tuesday: IQIA Holdings (IQV), Vertex (VRTX) and Arrowhead Pharmaceuticals (ARWR)
  • Monday: BioNTech (BNTX), Moderna (MRNA) and Regenxbio (RGNX)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.